Cargando…

KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy

PURPOSE: Our aim was to verify whether KIF20A has the potential to serve as a prognostic marker for female patients with estrogen receptor (ER)-positive breast cancer (BC) and treated with tamoxifen (TAM). PATIENTS AND METHODS: Online tools were used to investigate the potential correlation between...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Xuchen, Li, Sainan, Gao, Wei, Shi, Jiajie, Cheng, Meng, Mi, Yunzhe, Liu, Yueping, Sang, Meixiang, Li, Ziyi, Geng, Cuizhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455948/ https://www.ncbi.nlm.nih.gov/pubmed/37637711 http://dx.doi.org/10.2147/IJGM.S425918

Ejemplares similares

Effect of gastrointestinal microbiome and its diversity on the expression of tumor-infiltrating lymphocytes in breast cancer
por: Shi, Jiajie, et al.
Publicado: (2019)

miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets
por: Klinge, Carolyn M.
Publicado: (2015)

Decreased BRCA1 Confers Tamoxifen Resistance in Breast Cancer Cells by Altering Estrogen Receptor-Coregulator Interactions
por: Wen, Jie, et al.
Publicado: (2008)

Positive effect of tamoxifen as part of adjuvant chemo-endocrine therapy for breast cancer. Hokkaido Adjuvant Chemo-Endocrine Therapy for Breast Cancer Study Group.
por: Uchino, J., et al.
Publicado: (1994)

Role of PAX2 in breast cancer verified by bioinformatics analysis and in vitro validation
por: Yang, Shan, et al.
Publicado: (2023)

PTEN promoter methylation predicts 10-year prognosis in hormone receptor-positive early breast cancer patients who received adjuvant tamoxifen endocrine therapy
por: Fan, Yu, et al.
Publicado: (2022)

Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab
por: Wang, Xinle, et al.
Publicado: (2019)

MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy
por: Zhong, XiaoRong, et al.
Publicado: (2016)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis
por: Zhang, Wenshan, et al.
Publicado: (2022)

Author Correction: Epigenetic study of early breast cancer (EBC) based on DNA methylation and gene integration analysis
por: Zhang, Wenshan, et al.
Publicado: (2022)

HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study
por: Shi, Jiajie, et al.
Publicado: (2023)

Progestins and the endometrium in patients receiving tamoxifen
Publicado: (1999)

ZEB1-Mediated Transcriptional Upregulation of circWWC3 Promotes Breast Cancer Progression through Activating Ras Signaling Pathway
por: Meng, Lingjiao, et al.
Publicado: (2020)

circRNF10 Regulates Tumorigenic Properties and Natural Killer Cell-Mediated Cytotoxicity against Breast Cancer through the miR-934/PTEN/PI3k-Akt Axis
por: Liu, Fei, et al.
Publicado: (2022)

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
por: Jiang, Cen, et al.
Publicado: (2023)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

Modulation of estrogen related receptor alpha activity by the kinesin KIF17
por: Seneviratne, AM Pramodh Bandara, et al.
Publicado: (2017)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

Assisted computer and imaging system improve accuracy of breast tumor size assessment after neoadjuvant chemotherapy
por: Zhang, Meng, et al.
Publicado: (2021)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Prognostic significance of KIF2A and KIF20A expression in human cancer: A systematic review and meta-analysis
por: Li, Xing, et al.
Publicado: (2019)

Review of bone health in women with estrogen receptor–positive breast cancer receiving endocrine therapy
por: Malagrinò, Matteo, et al.
Publicado: (2023)

The Regulation of MS-KIF18A Expression and Cross Talk with Estrogen Receptor
por: Zusev, Margalit, et al.
Publicado: (2009)

Antibiotics modulate neoadjuvant therapy efficiency in patients with breast cancer: a pilot analysis
por: Zhang, Xi, et al.
Publicado: (2021)

SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
por: Huang, Yu-Hsiang, et al.
Publicado: (2018)

Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
por: Madeira, Marcelo, et al.
Publicado: (2013)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
por: Nordenskjöld, Anna, et al.
Publicado: (2016)

Upregulation of KIF20A correlates with poor prognosis in gastric cancer
por: Sheng, Yi, et al.
Publicado: (2018)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Estrogen Receptor (ER)-α36 Is Involved in Estrogen- and Tamoxifen-Induced Neuroprotective Effects in Ischemic Stroke Models
por: Zou, Wei, et al.
Publicado: (2015)

Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
por: Dowsett, M., et al.
Publicado: (1984)

miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2
por: Liu, Fei, et al.
Publicado: (2018)

Level of Combined Estrogen and Progesterone Receptor Expression Determines the Eligibility for Adjuvant Endocrine Therapy in Breast Cancer Patients
por: Ahn, Jee Hyun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q32fck7vpdroedui99vafgbj1u